Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHA:605033)
21.61
+0.38 (1.79%)
Feb 6, 2026, 3:00 PM CST
SHA:605033 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 867.12 | 881.01 | 694.02 | 905.41 | 841.93 | 562.54 |
Other Revenue | 4.52 | 4.52 | 5.01 | 0.63 | 0.56 | 5.98 |
| 871.63 | 885.53 | 699.03 | 906.05 | 842.49 | 568.52 | |
Revenue Growth (YoY) | 13.47% | 26.68% | -22.85% | 7.54% | 48.19% | 10.24% |
Cost of Revenue | 628.39 | 654.14 | 478.04 | 528.82 | 532.38 | 368.03 |
Gross Profit | 243.25 | 231.39 | 220.99 | 377.23 | 310.11 | 200.49 |
Selling, General & Admin | 155.4 | 141.19 | 119.27 | 153.18 | 116.7 | 61.48 |
Research & Development | 84.93 | 74.33 | 58.53 | 80.04 | 63.81 | 51.36 |
Other Operating Expenses | 7.32 | 2.23 | 2.75 | 3.45 | 2.9 | 2.26 |
Operating Expenses | 241.26 | 212.51 | 178.09 | 242.66 | 187.05 | 115.47 |
Operating Income | 1.98 | 18.88 | 42.9 | 134.57 | 123.06 | 85.02 |
Interest Expense | -0.03 | -0.01 | -0.38 | -0.98 | -3.31 | -0.85 |
Interest & Investment Income | 8.64 | 9.33 | 6.58 | 6.86 | 2.61 | 3.51 |
Currency Exchange Gain (Loss) | 0.02 | 0.02 | 0 | - | 0.06 | 0.01 |
Other Non Operating Income (Expenses) | -1.29 | -0.15 | -0.13 | -0.11 | 0.08 | -0.1 |
EBT Excluding Unusual Items | 9.32 | 28.07 | 48.97 | 140.34 | 122.5 | 87.59 |
Gain (Loss) on Sale of Investments | 0.28 | 0.47 | - | -0.07 | - | - |
Gain (Loss) on Sale of Assets | -0.04 | -0.04 | -0.04 | -0.12 | -0.02 | -0.1 |
Asset Writedown | 3.99 | 0 | 0.01 | - | - | - |
Other Unusual Items | 9.35 | 9.35 | 13.47 | 12.21 | 16.35 | 1.89 |
Pretax Income | 22.9 | 37.86 | 62.41 | 152.37 | 138.83 | 89.39 |
Income Tax Expense | -6.87 | 1 | 4.85 | 7.28 | 13.09 | 10.65 |
Net Income | 29.78 | 36.86 | 57.56 | 145.09 | 125.74 | 78.73 |
Net Income to Common | 29.78 | 36.86 | 57.56 | 145.09 | 125.74 | 78.73 |
Net Income Growth | -2.82% | -35.96% | -60.33% | 15.38% | 59.70% | 3.25% |
Shares Outstanding (Basic) | 136 | 137 | 134 | 136 | 110 | 101 |
Shares Outstanding (Diluted) | 136 | 137 | 134 | 136 | 110 | 101 |
Shares Change (YoY) | 1.18% | 1.99% | -1.29% | 22.93% | 9.27% | 1.93% |
EPS (Basic) | 0.22 | 0.27 | 0.43 | 1.07 | 1.14 | 0.78 |
EPS (Diluted) | 0.22 | 0.27 | 0.43 | 1.07 | 1.14 | 0.78 |
EPS Growth | -3.95% | -37.21% | -59.81% | -6.14% | 46.15% | 1.30% |
Free Cash Flow | 55.75 | 121.59 | 131.1 | 17.12 | -215.28 | 13.17 |
Free Cash Flow Per Share | 0.41 | 0.89 | 0.98 | 0.13 | -1.95 | 0.13 |
Dividend Per Share | 0.150 | 0.145 | 0.150 | 0.220 | 0.190 | - |
Dividend Growth | -23.08% | -3.33% | -31.82% | 15.79% | - | - |
Gross Margin | 27.91% | 26.13% | 31.61% | 41.63% | 36.81% | 35.27% |
Operating Margin | 0.23% | 2.13% | 6.14% | 14.85% | 14.61% | 14.95% |
Profit Margin | 3.42% | 4.16% | 8.23% | 16.01% | 14.92% | 13.85% |
Free Cash Flow Margin | 6.40% | 13.73% | 18.75% | 1.89% | -25.55% | 2.32% |
EBITDA | 22.08 | 39.31 | 63.77 | 150.05 | 135.54 | 95.49 |
EBITDA Margin | 2.53% | 4.44% | 9.12% | 16.56% | 16.09% | 16.80% |
D&A For EBITDA | 20.1 | 20.43 | 20.87 | 15.47 | 12.48 | 10.47 |
EBIT | 1.98 | 18.88 | 42.9 | 134.57 | 123.06 | 85.02 |
EBIT Margin | 0.23% | 2.13% | 6.14% | 14.85% | 14.61% | 14.95% |
Effective Tax Rate | - | 2.64% | 7.78% | 4.78% | 9.43% | 11.92% |
Revenue as Reported | 871.63 | 885.53 | 699.03 | 906.05 | 842.49 | 568.52 |
Advertising Expenses | - | 17.2 | 10.78 | 27.33 | 11.56 | 8.17 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.